S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Elon Musk restores X account of conspiracy theorist Alex Jones
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Dozens of animals taken from Virginia roadside zoo as part of investigation
The EU wants to put a tax on emissions from imports. It's irked some other nations at COP28
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
AP PHOTOS: Moscow hosts a fashion forum with designers from Brazil, China, India and South Africa
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Elon Musk restores X account of conspiracy theorist Alex Jones
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Dozens of animals taken from Virginia roadside zoo as part of investigation
The EU wants to put a tax on emissions from imports. It's irked some other nations at COP28
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
AP PHOTOS: Moscow hosts a fashion forum with designers from Brazil, China, India and South Africa
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Elon Musk restores X account of conspiracy theorist Alex Jones
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Dozens of animals taken from Virginia roadside zoo as part of investigation
The EU wants to put a tax on emissions from imports. It's irked some other nations at COP28
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
AP PHOTOS: Moscow hosts a fashion forum with designers from Brazil, China, India and South Africa
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Elon Musk restores X account of conspiracy theorist Alex Jones
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Dozens of animals taken from Virginia roadside zoo as part of investigation
The EU wants to put a tax on emissions from imports. It's irked some other nations at COP28
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
AP PHOTOS: Moscow hosts a fashion forum with designers from Brazil, China, India and South Africa

RxSight Stock Price, News & Analysis (NASDAQ:RXST)

$34.97
+0.81 (+2.37%)
(As of 12/8/2023 ET)
Compare
Today's Range
$33.74
$35.04
50-Day Range
$20.91
$34.97
52-Week Range
$10.29
$35.04
Volume
542,676 shs
Average Volume
603,532 shs
Market Capitalization
$1.25 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$30.71

RxSight MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.80 Rating Score
Upside/​Downside
12.2% Downside
$30.71 Price Target
Short Interest
Healthy
4.56% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.09mentions of RxSight in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$7.10 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.53) to ($1.28) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.88 out of 5 stars

Medical Sector

613th out of 933 stocks

Ophthalmic Goods Industry

4th out of 6 stocks


RXST stock logo

About RxSight Stock (NASDAQ:RXST)

RxSight, Inc., an ophthalmic medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.

RXST Stock Price History

RXST Stock News Headlines

RxSight (NASDAQ:RXST) Now Covered by Analysts at Morgan Stanley
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology
Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology
Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Here's what Wall Street expects from RxSight's earnings report
RxSight (NASDAQ: RXST)
J.P. Morgan Sticks to Their Buy Rating for RxSight (RXST)
Where RxSight Stands With Analysts
RxSight's Earnings: A Preview
See More Headlines
Receive RXST Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for RxSight and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/09/2023
Today
12/10/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/04/2024

Industry, Sector and Symbol

Industry
Ophthalmic goods
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RXST
Fax
N/A
Employees
292
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$30.71
High Stock Price Target
$36.00
Low Stock Price Target
$20.00
Potential Upside/Downside
-12.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

Net Income
$-66,760,000.00
Pretax Margin
-71.81%

Debt

Sales & Book Value

Annual Sales
$49.01 million
Book Value
$3.24 per share

Miscellaneous

Free Float
28,284,000
Market Cap
$1.25 billion
Optionable
Not Optionable
Beta
1.07
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Dr. Ronald M. Kurtz M.D. (Age 60)
    President, CEO & Director
    Comp: $1.03M
  • Ms. Shelley B. Thunen (Age 69)
    CFO & Assistant Secretary
    Comp: $651.36k
  • Dr. Ilya Goldshleger Ph.D. (Age 48)
    Chief Operating Officer
    Comp: $657.81k
  • Mr. Eric J. Weinberg (Age 62)
    Chief Commercial Officer
    Comp: $638.9k
  • Ms. Rebecca Williston
    Vice President of Accounting & Finance
  • Mr. Matt Haller Ph.D.
    Chief Technology Officer
  • Alex Huang
    Investor Relations
  • Mr. Roy Freeman
    Vice President of Marketing
  • Ms. Caroline Vaughn
    Vice President of Human Resources
  • Mr. Scott Gaines
    Senior VP of Commercial Operations & Business Process














RXST Stock Analysis - Frequently Asked Questions

Should I buy or sell RxSight stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for RxSight in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" RXST shares.
View RXST analyst ratings
or view top-rated stocks.

What is RxSight's stock price target for 2024?

5 Wall Street analysts have issued 1 year price targets for RxSight's shares. Their RXST share price targets range from $20.00 to $36.00. On average, they expect the company's share price to reach $30.71 in the next twelve months. This suggests that the stock has a possible downside of 12.2%.
View analysts price targets for RXST
or view top-rated stocks among Wall Street analysts.

How have RXST shares performed in 2023?

RxSight's stock was trading at $12.67 on January 1st, 2023. Since then, RXST stock has increased by 176.0% and is now trading at $34.97.
View the best growth stocks for 2023 here
.

When is RxSight's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 4th 2024.
View our RXST earnings forecast
.

How were RxSight's earnings last quarter?

RxSight, Inc. (NASDAQ:RXST) issued its quarterly earnings data on Thursday, November, 9th. The company reported ($0.35) EPS for the quarter, beating analysts' consensus estimates of ($0.42) by $0.07. The firm had revenue of $22.20 million for the quarter, compared to analysts' expectations of $20.81 million. RxSight had a negative trailing twelve-month return on equity of 39.77% and a negative net margin of 71.87%.

What ETF holds RxSight's stock ?

Invesco Dorsey Wright Healthcare Momentum ETF holds 53,792 shares of RXST stock, representing 1.07% of its portfolio.

When did RxSight IPO?

(RXST) raised $125 million in an IPO on Friday, July 30th 2021. The company issued 7,350,000 shares at a price of $16.00-$18.00 per share.

Who are RxSight's major shareholders?

RxSight's stock is owned by a variety of institutional and retail investors. Top institutional investors include Artisan Partners Limited Partnership (6.84%), Lord Abbett & CO. LLC (4.57%), Morgan Stanley (3.38%), JPMorgan Chase & Co. (1.54%), Atika Capital Management LLC (1.43%) and Federated Hermes Inc. (0.88%). Insiders that own company stock include Bakker Juliet Tammenoms, Jesse Anderson Corley and Shweta Maniar.
View institutional ownership trends
.

How do I buy shares of RxSight?

Shares of RXST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:RXST) was last updated on 12/10/2023 by MarketBeat.com Staff

My Account -